HCPCS Level II · Temporary national codes (non-Medicare)
S3840Dna analysis for germline mutations of the ret proto-oncogene for susceptibility to multiple endocrine neoplasia type 2
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About S3840
S3840 is an HCPCS Level II code in the S series (temporary national codes (non-Medicare)), describing dna analysis for germline mutations of the ret proto-oncogene for susceptibility to multiple endocrine neoplasia type 2.
It was added to HCPCS effective 07/01/2003.
Its Medicare coverage code is "I", meaning it is not payable by Medicare (another code or method is used).
Details
- Short description
- Dna analysis ret-oncogene
- Date added
- 07/01/2003
- Action effective
- 07/01/2003
- BETOS
- Z2
Related S38xx codes
- S3800Genetic testing for amyotrophic lateral sclerosis (als)
- S3841Genetic testing for retinoblastoma
- S3842Genetic testing for von hippel-lindau disease
- S3844Dna analysis of the connexin 26 gene (gjb2) for susceptibility to congenital, profound deafness
- S3845Genetic testing for alpha-thalassemia
- S3846Genetic testing for hemoglobin e beta-thalassemia
- S3849Genetic testing for niemann-pick disease
- S3850Genetic testing for sickle cell anemia
- S3852Dna analysis for apoe epsilon 4 allele for susceptibility to alzheimer's disease
- S3853Genetic testing for myotonic muscular dystrophy
- S3854Gene expression profiling panel for use in the management of breast cancer treatment
- S3861Genetic testing, sodium channel, voltage-gated, type v, alpha subunit (scn5a) and variants for suspected brugada syndrome
Common questions about S3840
Is HCPCS S3840 still valid?
- Yes. S3840 is active in the CMS October 2026 HCPCS file.
Does Medicare cover S3840?
- Its coverage code is "I": it is not payable by Medicare (another code or method is used). Check the local coverage determination for your region.